Novartis autoimmune cell-therapy program reports setbacks after deaths
A Novartis autoimmune cell-therapy program suffered a setback following reported deaths, while the company's primary objective for an MS drug was reportedly achieved. The supplied headline gives no further details on the number or circumstances of the deaths.
By DoomRadar · Published on DoomRadar .
Why it matters
Safety concerns could affect clinical development and access to emerging treatments.
Related source links
These links were collected with this event. Recorded source dates may reflect when a link was found. Article publication dates are shown only when available from the source. Open the originals for their full context.
- Novartis-Aktie in Grün: Rückschlag bei Autoimmun-Zelltherapie nach Todesfällen - Primäre Ziele bei MS-Medikament erreicht ↗finanzen.ch · Recorded source date: Sep 5, 2026, 10:46 AM UTC
AI-assisted, source-based analysis. Methodology · Report a correction